Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Alto Neuroscience, Inc. (ANRO)

Alto Neuroscience Q2 net loss widens to $27.6 million from $17.7 million

Negative Impact 3 of 5 earnings Written later

Alto Neuroscience reported a second-quarter 2026 net loss of $27.6 million, up from $17.7 million a year earlier, as research and development spending rose to $22.1 million from $13.1 million. The company said it had about $338 million in pro forma cash after a July 2026 offering, which it expects to fund planned operations through 2030, and it added a Phase 3 monotherapy trial of ALTO-207 to its development plan.

Key points

  • Q2 2026 net loss was $27.6 million, versus $17.7 million in Q2 2025; net loss per share was $0.65 in both periods.
  • R&D expenses were $22.1 million versus $13.1 million; G&A expenses were $7.0 million versus $5.6 million.
  • Cash, cash equivalents, and restricted cash were $244.2 million at June 30, 2026, versus $177.0 million at December 31, 2025.
  • July 2026 registered direct offering raised gross proceeds of about $100.0 million; pro forma cash is about $338 million.

The filing

CompanyAlto Neuroscience, Inc. (ANRO)
Form8-K, current report
Filed with the SECAug 12, 2026, 4:14 PM ET
Accession number0001999480-26-000022

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.